BioSpace News Archive

InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today financial results for the three and nine months ended September 30, 2020.

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), today announced that it has treated the first patient in the sixth and final cohort of its National Cancer Institute (NCI)-supported, multi-center ReSPECT™ Phase 1 dose-finding clinical trial evaluating Rhenium NanoLiposomes (RNL™) for the treatment of recurrent glioblastoma (GBM).

Amarin Corporation plc (NASDAQ:AMRN) today announced that new scientific findings that add to the growing body of knowledge on VASCEPA® (icosapent ethyl) in patients at risk for major adverse cardiovascular events will be presented during the American Heart Association’s (AHA) Virtual Scientific Sessions 2020, being held from November 13 - November 17, 2020.

Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today reported its operating and financial results for the third quarter ended September 30, 2020.

Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies, today announced the appointment of Charles Williams as chief financial officer

Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced its third-quarter 2020 financial results.

Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal care, today announced that Vice President and General Manager of Worldwide Robotics Liane Teplitsky will be presenting at the SVB Leerink CybeRx Series: Devices & DNA – Future of Orthopedic Robotics conference on Thursday, November 12, at 12:30 p.m. Eastern Time.

Eli Lilly and Company (NYSE: LLY) announced today it will share new Taltz® (ixekizumab) data from multiple long-term and post-hoc analyses that indicate sustained efficacy in patients with psoriasis and psoriatic arthritis.

Q32 Bio, a biotechnology company developing biologic therapeutics to restore healthy immune regulation, today announced the completion of a $60 million Series B financing co-led by OrbiMed Advisors and Acorn Bioventures.

Company Will Report Data from Phase 2a Sensorineural Hearing Loss (SNHL) Study in Late Q1 2021 First Patient Dosed in Phase 1b Study of Age-Related Hearing Loss; Additional Phase 1b Study for Severe SNHL Patients to Start This Quarter